Once-weekly glucagon-like peptide 1 receptor agonists

J Pak Med Assoc. 2015 Jul;65(7):796-8.

Abstract

The once-weekly glucagon-like peptide 1 receptor agonists (QW GLP1RA) represent a major advancement in diabetes pharmaco-therapeutics. This review describes the basic, clinical, and comparative pharmacology of this novel class of drugs. It highlights the clinical placement and posology of these drugs.

Keywords: Albiglutide, dulaglutide, exenatide QW, semaglutide..

Publication types

  • Review

MeSH terms

  • Delayed-Action Preparations
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Drug Administration Schedule
  • Exenatide
  • Glucagon-Like Peptide 1 / administration & dosage
  • Glucagon-Like Peptide 1 / analogs & derivatives
  • Glucagon-Like Peptide-1 Receptor / agonists*
  • Glucagon-Like Peptides / administration & dosage
  • Glucagon-Like Peptides / analogs & derivatives
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Immunoglobulin Fc Fragments / administration & dosage
  • Incretins / administration & dosage*
  • Peptides / administration & dosage
  • Recombinant Fusion Proteins / administration & dosage
  • Venoms / administration & dosage

Substances

  • Delayed-Action Preparations
  • Glucagon-Like Peptide-1 Receptor
  • Hypoglycemic Agents
  • Immunoglobulin Fc Fragments
  • Incretins
  • Peptides
  • Recombinant Fusion Proteins
  • Venoms
  • rGLP-1 protein
  • Glucagon-Like Peptides
  • Glucagon-Like Peptide 1
  • Exenatide
  • dulaglutide